Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 10Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Skin Neoplasms 6Prostatic Neoplasms 5Neoplasm Metastasis 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Sarcoma 3Pancreatic Neoplasms 3Mycosis Fungoides 3Carcinoma, Squamous Cell 3Carcinoma, Hepatocellular 3Carcinoma, Basal Cell 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Carcinoma, Anaplastic 2Rectal Neoplasms 2Oropharyngeal Neoplasms 2Mouth Neoplasms 2Mesothelioma, Malignant 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Paclitaxel 7Doxorubicin 5pembrolizumab 4pazopanib 4Gemcitabine 4Bevacizumab 4durvalumab 3Radiotherapy 3Propranolol 3Docetaxel 3regorafenib 2cemiplimab 2Surveys and Questionnaires 2Sunitinib 2Standard of Care 2Nivolumab 2Ifosfamide 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trebananib 1trastuzumab duocarmazine 1talimogene laherparepvec 1talazoparib 1spartalizumab 1sintilimab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hemangiosarcoma × cemiplimab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04873375 2024-10-31

Cemiplimab for Secondary Angiosarcomas

Radboud University Medical Center

Phase 2 Completed
18 enrolled
Sarcoma

Hemangiosarcoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡